ACCENT: AMP945 in Combination with Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer

NCT05355298 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

62

Enrollment

INDUSTRY

Sponsor class

Conditions

Pancreatic Cancer
PDAC
Pancreatic Ductal Adenocarcinoma

Interventions

DRUG: AMP945 ascending doses
DRUG: AMP945 RP2D

Sponsor

Amplia Therapeutics Limited